Comparative analysis of vaccine and disease induced immunity and immunological evaluation of COVID-19 vaccines on effectiveness and safety

Acronym

COVIDIMMUNITY

Description of the granted funding

A novel coronavirus, SARS-CoV-2 started the first coronavirus pandemic in early 2020. The virus spreads mainly via respiratory droplets and occasionally the disease leads to a severe lower respiratory tract infection, acute respiratory failure and death. Globally, as of June 2020 there have been nearly 6,5 million cases and 400 000 deaths due to COVID-19 infection. Our research consortium concentrates on analyzing the activation and specificity of antibody and cell-mediated immunity in COVID-19 infected and vaccinated individuals. We intend to identify the viral targets of protective immunity and in longitudinal follow-up studies analyze the natural infection and COVID-19 vaccine-induced immunity at individual and population level. The study has a significant public health impact and the data produced by the project is likely to enhance pandemic preparedness and response as well as to direct coronavirus vaccination policy in Finland.
Show more

Starting year

2020

End year

2022

Granted funding



Ilkka Julkunen Orcid -palvelun logo
700 000 €

Role in consortium of the Academy of Finland

Leader

Other consortium parties

Partner
University of Helsinki (336411)
499 776 €
Partner
Finnish Institute for Health and Welfare (336431)
500 000 €

Funder

Research Council of Finland

Funding instrument

Targeted Academy projects

Other information

Funding decision number

336410

Fields of science

Biomedicine

Research fields

Biolääketieteet

Themes

Lisätalousarvio III 2020

Identified topics

covid, pandemic, vaccines